{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:11:18Z","timestamp":1794366678959,"version":"4.9.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases\u2013Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.<\/jats:p>","DOI":"10.1093\/cid\/ciq257","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T02:43:44Z","timestamp":1296701024000},"page":"e103-e120","source":"Crossref","is-referenced-by-count":2466,"title":["International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases"],"prefix":"10.1093","volume":"52","author":[{"given":"Kalpana","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, Veterans Affairs Boston Health Care System and Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Hooton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami Miller School of Medicine, University of Miami, Miami Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt G.","family":"Naber","sequence":"additional","affiliation":[{"name":"Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Wullt","sequence":"additional","affiliation":[{"name":"Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colgan","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Maryland, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Division of Infectious Diseases Olive View-UCLA Medical Center, Slymar, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay E.","family":"Nicolle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Department of Medical Mirobiology University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Raz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Ha'Emek Medical Center, Afula, and Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Deptartment of urology, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Soper","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology and Medicine, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"2020110410411453000_bib1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.162.1.41","article-title":"National patterns in the treatment of urinary tract infections in women by ambulatory care physicians","volume":"162","author":"Huang","year":"2002","journal-title":"Archives of internal medicine"},{"key":"2020110410411453000_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2710.2003.00537.x","article-title":"Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money","volume":"29","author":"Kahan","year":"2004","journal-title":"Journal of clinical pharmacy and therapeutics"},{"key":"2020110410411453000_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/archinte.166.6.635","article-title":"Current antibiotic therapy for isolated urinary tract infections in women","volume":"166","author":"Kallen","year":"2006","journal-title":"Archives of internal medicine"},{"key":"2020110410411453000_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1070-3241(16)30274-7","article-title":"Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO","volume":"22","author":"O'Connor","year":"1996","journal-title":"The Joint Commission journal on quality improvement"},{"key":"2020110410411453000_bib6","first-page":"775","article-title":"Evaluating guidelines","volume":"44","author":"Stamm","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib7","first-page":"66","article-title":"Fosfomycin for urinary tract infections","volume":"39","year":"1997","journal-title":"Med Lett Drugs Ther"},{"key":"2020110410411453000_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410411453000_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0924-8579(03)00229-2","article-title":"Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study","volume":"22","author":"Kahlmeter","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"key":"2020110410411453000_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2006.02.009","article-title":"Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)","volume":"27","author":"Zhanel","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jac\/dkp387","article-title":"Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use","volume":"65","author":"Sundqvist","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020110410411453000_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1086\/339491","article-title":"Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan","volume":"34","author":"Brown","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/jac\/dkg146","article-title":"Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections","volume":"51","author":"Metlay","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410411453000_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0002-9343(03)00372-3","article-title":"Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates","volume":"115","author":"Burman","year":"2003","journal-title":"Am J Med"},{"key":"2020110410411453000_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.01200-07","article-title":"Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis","volume":"52","author":"Colgan","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410411453000_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","article-title":"Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"2020110410411453000_bib18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1086\/592250","article-title":"Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis","volume":"47","author":"Talan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4065\/79.8.1048","article-title":"Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance","volume":"79","author":"Miller","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"2020110410411453000_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0891-5520(03)00006-0","article-title":"Emerging antibiotic resistance in urinary tract pathogens","volume":"17","author":"Gupta","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"2020110410411453000_bib21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/339812","article-title":"Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens","volume":"34","author":"Raz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib22","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/382690","article-title":"\"Collateral damage\" from cephalosporin or quinolone antibiotic therapy","volume":"38","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib23","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1086\/500663","article-title":"Extended-spectrum \u03b2-lactamases and clinical outcomes: current data","volume":"42","author":"Ramphal","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","article-title":"Pivmecillinam\u2013therapy of choice for lower urinary tract infection","volume":"22","author":"Graninger","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF01643751","article-title":"Influence of fosfomycin on the intestinal and pharyngeal flora of man","volume":"19","author":"Knothe","year":"1991","journal-title":"Infection"},{"key":"2020110410411453000_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1179\/joc.1997.9.3.203","article-title":"Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitroffurantoin on fecal flora of women with recurrent urinary tract infections","volume":"9","author":"Mavromanolakis","year":"1997","journal-title":"J Chemother"},{"key":"2020110410411453000_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1473-3099(01)00066-4","article-title":"Effect of antimicrobial agents on the ecological balance of human microflora","volume":"1","author":"Sullivan","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"2020110410411453000_bib28","first-page":"729","article-title":"Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women","volume":"52","author":"Christiaens","year":"2002","journal-title":"Br J Gen Pract"},{"key":"2020110410411453000_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02813430601183074","article-title":"Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project","volume":"25","author":"Ferry","year":"2007","journal-title":"Scand J Prim Health Care"},{"key":"2020110410411453000_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995 to 2002","volume":"118","author":"Linder","year":"2005","journal-title":"Am J Med"},{"key":"2020110410411453000_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.17226\/1626","article-title":"Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines","volume-title":"Clinical practice guidelines: directions for a new program","author":"Field","year":"1990"},{"issue":"9","key":"2020110410411453000_bib32","first-page":"1193","article-title":"Canadian Task Force on the Periodic Health Examination. The periodic health examination","volume":"121","year":"1979","journal-title":"Can Med Assoc J"},{"key":"2020110410411453000_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1179\/joc.1998.10.2.122","article-title":"Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial","volume":"10","author":"Pimentel","year":"1998","journal-title":"J Chemother"},{"key":"2020110410411453000_bib34","article-title":"Guidelines on urological infections","author":"Grabe"},{"key":"2020110410411453000_bib35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jac\/dkh414","article-title":"Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim\/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study","volume":"54","author":"Arredondo-Garcia","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020110410411453000_bib36","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"key":"2020110410411453000_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/43.suppl_1.67","article-title":"A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection","volume":"43","author":"Iravani","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2020110410411453000_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/AAC.47.3.897-900.2003","article-title":"Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women","volume":"47","author":"Kavatha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410411453000_bib39","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0149-2918(00)86734-X","article-title":"Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection","volume":"21","author":"Stein","year":"1999","journal-title":"Clin Ther"},{"key":"2020110410411453000_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-8579(98)00021-1","article-title":"A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women","volume":"10","author":"Minassian","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410411453000_bib42","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"168","author":"Rodriguez-Bano","year":"2008","journal-title":"Arch Intern Med"},{"key":"2020110410411453000_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/00365540110080728","article-title":"Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women","volume":"34","author":"Nicolle","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"2020110410411453000_bib44","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1128\/AAC.42.9.2262","article-title":"Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group","volume":"42","author":"Henry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410411453000_bib45","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0149-2918(99)80018-6","article-title":"Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. parfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group","volume":"21","author":"Henry","year":"1999","journal-title":"Clin Ther"},{"key":"2020110410411453000_bib46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijantimicag.2003.12.017","article-title":"Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0090-4295(01)01562-X","article-title":"Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens","volume":"59","author":"Richard","year":"2002","journal-title":"Urology"},{"key":"2020110410411453000_bib48","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.49.10.4137-4143.2005","article-title":"Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women","volume":"49","author":"Fourcroy","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410411453000_bib49","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0149-2918(02)80099-6","article-title":"Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women","volume":"24","author":"Henry","year":"2002","journal-title":"Clin Ther"},{"key":"2020110410411453000_bib50","first-page":"469","article-title":"Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial","volume":"170","author":"Vogel","year":"2004","journal-title":"CMAJ"},{"key":"2020110410411453000_bib51","first-page":"50","article-title":"Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women","volume":"8","author":"Auquer","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"2020110410411453000_bib52","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.293.8.949","article-title":"Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial","volume":"293","author":"Hooton","year":"2005","journal-title":"JAMA"},{"key":"2020110410411453000_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1086\/422145","article-title":"Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy","volume":"39","author":"Hooton","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410411453000_bib54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0149-2918(00)80054-5","article-title":"Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection","volume":"22","author":"Leigh","year":"2000","journal-title":"Clin Ther"},{"key":"2020110410411453000_bib55","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2020110410411453000_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2020110410411453000_bib57","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/01.ju.0000106191.11936.64","article-title":"Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis","volume":"171","author":"Talan","year":"2004","journal-title":"J Urol"},{"key":"2020110410411453000_bib58","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","article-title":"Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410411453000_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/003655401750173922","article-title":"Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime","volume":"33","author":"Cronberg","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2020110410411453000_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/emj.19.1.19","article-title":"Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women: a randomised controlled trial","volume":"19","author":"Sanchez","year":"2002","journal-title":"Emerg Med J"},{"key":"2020110410411453000_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/519268","article-title":"Population-based epidemiologic analysis of acute pyelonephritis","volume":"45","author":"Czaja","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/52\/5\/e103\/34128706\/ciq257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/52\/5\/e103\/34128706\/ciq257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T11:28:27Z","timestamp":1604489307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/52\/5\/e103\/388285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,3,1]]},"published-print":{"date-parts":[[2011,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciq257","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,3,1]]},"published":{"date-parts":[[2011,3,1]]}}}